Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - Bosakitug is a Potential Best-in-Class Investigational Monoclonal Antibody with Demonstrated Superior Potency, Residence Time, and Affinity to Thymic Stromal Lymphopoietin (TSLP) - - Top Line Results Expected in the Second Half of 2026 - WAYNE, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a randomized,...
Aclaris Therapeutics to Participate in Two June Healthcare Conferences WAYNE, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in June. On Wednesday June 4, 2025, at 10:30 AM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during Jefferies Global Healthc...
PetMed Express, Inc. Sets Fourth Quarter and Full Fiscal Year 2025 Earnings Call DELRAY BEACH, Fla., May 27, 2025 (GLOBE NEWSWIRE) -- , dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) will hold a conference call on Tuesday, June 10, 2025 at 4:30pm Eastern Time to discuss its financial results for the fourth quarter and full fiscal year ended March 31, 2025. Financial results will be issued in a press release prior to the call. PETS management will host the conference call, followed by a question-and-answer period. Please call the conference telephone number 5-10 minutes prior...
Two Directors at Etsy Inc sold 2,800 shares at between 46.890USD and 47.010USD. The significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series WAYNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Aclaris’ Chief Executive Officer Neal Walker and other members of the Aclaris senior leadership team will participate in a fireside chat during the virtual HC Wainwright “HCW@Home” series. The virtual fireside chat will take place on Friday May 16, 2025, at 1:00 PM EDT. A live and arch...
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced Potency of Bosakitug (ATI-045) and Opportunity for Development Partnerships - - Investigational New Drug (IND) Application for Bispecific Antibody ATI-052 Cleared by U.S. Food and Drug Administration - WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) ...
PetMed Express, Inc. and Dutch Announce Partnership to Provide Accessible Telehealth Services for Pets Strategic Collaboration Marks PetMeds’ Latest Move in Expanding Its Pet Healthcare Ecosystem DELRAY BEACH, Fla. and OAKLAND, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., parent company of PetMeds and PetCareRx (Nasdaq: PETS), today announced a new strategic partnership with virtual veterinary care provider . The collaboration marks PetMeds’ latest move to expand its provider ecosystem with affordable, accessible pet healthcare options. The new partnership will enable ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.